Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Hematology
•
Vasculitis
•
ANCA Vasculitis
•
General Rheumatology
•
Nephrology
Would you start anticoagulation in a previously heathy patient with a new diagnosis of ANCA vasculitis (+PR3, RPGN, crescents on kidney biopsy) who presented with pancreatitis, splenic and renal infarcts and was also found to have CMV viremia?
Negative TEE and malignancy work up.
Related Questions
How would you approach management of a patient with ESRD on the transplant list who is found to have high titer APS labs (ACL, B2GP1, LAC)?
Do you extend the duration of maintenance therapy past 24 months for patients with ANCA glomerulonephritis who have multiple organ involvement?
How do you counsel patients who experience diarrhea from mycophenolate mofetil (Cellcept)?
Do you restrict topical diclofenac use in your patients with chronic kidney disease?
Do you perform genetic testing when patients have persistent hypogammaglobulinemia after rituximab therapy?
Do you routinely consider FDG PET/CT imaging for workup of fever of unknown origin?
When would you administer the next maintenance dose of rituximab in a patient with ANCA glomerulonephritis who last received an infusion six months ago and has low immunoglobulin levels and an undetectable CD-19 cell count?
Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?
What is your approach for steroid dosing for patients with ANCA vasculitis on induction treatment with rituximab, avacopan, and glucocorticoid therapy?
Do you prefer celecoxib over a nonselective NSAID in patients with chronic kidney disease?